Background
Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) is a condition of unknown origin that is characterized by severe fatigue for more than 6 months leading to significant disability. To fulfill the CFS/ME criteria as recommended by the Centers for Disease control (CDC), patients also have to report at least four out of eight of the accompanying symptoms (e.g. muscle pain, post-exertional fatigue, headache, etc.) [
1,
2]. With CFS/ME being an exclusionary diagnosis, patients often report to have symptoms for several years before being diagnosed [
3]. Most of the current case definitions suggest a collection of mandatory diagnostics to exclude common causes for fatigue such as anemia and thyroid illnesses [
1,
4], but there is a need for more specific tests to diagnose patients. Another advantage of such a test is that it might be easier to define CFS/ME subgroups [
5], for example those patients that would or would not respond to an immune intervention. Last but not least, a distinctive marker or set of markers may point to relevant pathogenetic mechanisms that can be further explored.
In the past years, numerous studies have been performed searching for potential biomarkers [
6]. Because of the resemblance of CFS/ME with symptoms that characterize immune activation, there has been a particular interest in the immune system with studies measuring lymphocyte subsets [
7,
8], cytokine production [
9‐
11], and single nucleotide polymorphisms in immune related genes [
12,
13]. However, despite a large number of studies conducted, this has not led to a unified conclusion useful for clinical practice. Studies are largely contradicting, and a recent systematic review on circulating cytokines did not find evidence for altered cytokine concentrations in CFS/ME, with the exception of transforming growth factor-beta (TGF-β) [
14]. TGF-β appeared to be elevated in 63% of the selected studies. This was also found in a recent study on cytokine signatures in CFS [
15]. Other cytokines were only elevated in a minority of studies, for example interleukin-1α (IL-1α) in 27% of the studies, interleukin 12 (IL-12) in 18%, interleukin 23 (IL-23) 25%, and interleukin 8 (IL-8) in 29% of studies. Some studies only found differences when differentiating between patients with long and short illness duration [
9,
16].
In order to make progress on the role of the immune system in CFS/ME, we have to critically review the studies that have been performed, and try to clarify the reasons for these discrepancies. When measuring circulating cytokines, several issues have to be taken into account. First, patient selection is important. Studies often combine different cohorts of patients, recruit employees as controls, or controls who participated in previous studies [
9,
17], and this may lead to different pre-analytical procedures. The latter is especially an important issue in this context. Cytokines may be released ex vivo by different circulating cells, and collection tubes, storage time, number of freeze–thaw cycles, and processing protocols have been found to be of major influence [
18,
19]. To make a reliable comparison between patients and controls, especially in CFS/ME where circulating cytokines are expected to be low, it is essential that the pre-analytical process in these groups is identical.
Another important issue is the type of analysis used to determine cytokine concentrations. Most studies measuring cytokines use antibody based enzyme-linked immuno sorbent assays (ELISA) [
14]. However, limitations of this technique are that multiplex forms of the assays often use only one antigen-binding antibody to detect the protein, which limits detection specificity as well as sensitivity [
20]. Sandwich ELISA achieves better performance by using pairs of antibodies for each targeted protein, but the assays typically need relatively large sample volumes for analyses of single protein species, limiting throughput and spending precious samples. By contrast, the proximity extension assay (PEA) uses dual antibody recognition with oligonucleotide-conjugated antibodies in multiplex assays with modest requirements for sample volumes [
20,
21]. Upon simultaneous binding of the correct pair of antibodies, their attached oligonucleotides anneal to each other and can be enzymatically extended, forming specific DNA sequences that can be quantified using quantitative real-time polymerase chain reactions (qPCR).
In this study, cytokine profiles of female CFS/ME patients participating in a randomized controlled trial on the effect of IL-1 inhibition on fatigue severity [
22] were compared with age- and gender-matched healthy neighborhood controls. The rationale of this RCT was that IL-1—despite the fact that it is notoriously difficult to measure in the circulation—may play a pathophysiological role in CFS, and its activity may be confined to the brain compartment [
23]. In addition to the cytokines included in the PEA platform, TGF-β and the IL-1 receptor antagonist (IL1-Ra), were measured separately using an ELISA. Pre-analytical procedures were identical for patients and controls. Furthermore, the effect of IL-1 inhibition using the IL-1-receptor antagonist anakinra for 1 month on circulating cytokine concentrations was assessed. As reported in detail elsewhere, the study did not demonstrate a beneficial therapeutic effect in these patients [
24].
Discussion
In this study differences in plasma cytokine profiles of 50 CFS/ME patients compared to 48 healthy age-matched neighborhood controls were evaluated using a PEA protein assay. The concentration of IL-12p40 and CSF-1 were significantly higher in CFS/ME patients. For the remaining cytokines of interest based on the current CFS/ME literature, no differences could be found comparing them individually. However, using the complete inflammatory profile, patients and controls could be discriminated using 22 variables with a positive association and 24 variables with a negative association.
IL-12b, also known as IL-12p40, was significantly higher in CFS/ME patients compared to healthy controls (p = 0.005). The IL-12p40 subunit is expressed by activated dendritic cells (DC) and combines with either subunit p35 or p19, to form IL-12 or IL-23 [
37]. IL-12 targets T-cells and NK-cells, in which it induces IFN-γ production [
38]. IL-23 has an important role in Th17 production, has an effect on memory T-cells, and appears to be critical in cerebral autoimmune inflammation [
39]. Previous studies in CFS/ME patient also found increased concentration of both IL-12 [
17,
40,
41], IL-12b [
9] and IL23 [
42]. A relationship between IL-12 and fatigue has been established in studies investigating the effect of administration of human recombinant IL-12 to treat ovarian cancer, and head and neck cancer [
43,
44]. A proportion of treated patients developed fatigue, and combined with other side effects such as fever and chills, this toxicity had dose-limiting consequences. Furthermore, increased concentrations of IL-12 and IL-23 have especially been associated with multiple sclerosis, in addition to psoriasis, inflammatory bowel disease, cancer and rheumatoid arthritis [
37]. However, in the light of the explorative nature of the current analysis, replication of this finding is important.
Increased concentrations of CSF-1 have not been previously been reported in CFS. CSF-1 or macrophage colony-stimulating factor (M-CSF) is a hematopoietic growth factor involved in proliferation and differentiation of monocytes and macrophages. Targeting CSF-1 has predominantly been described in cancer, where there appears to be an advantage when it is used in combination with other immune therapies [
45]. Interestingly, the role of CSF-1 in the development of sickness behavior has recently been assessed by Müller et al. [
46]. In this study, neutralization of the CSF-1 receptor prevented the development of sickness behavior in mice treated with an inflammatory stimulus. This behavioral response was mediated through increased IL-10 production. Increased IL-10 concentrations were also demonstrated in the hypothalamus, where the behavioral effect is most likely to be effected.
In contrast to the majority of previous studies measuring circulating cytokines, in this study there were no differences in TGF-β concentrations [
14]. TGF-β influences cell proliferation, migration, and differentiation, and is known for its dual role in cancer [
47]. TGF-β is released in large quantities by activated platelets [
48]. Several factors, such as blood sampling procedures [
49] and use of medication, influence the extent of platelet activation. A possible explanation for the increased TGF-β levels previously reported might be caused by differences in sample handling and drug use, which has recently been demonstrated [
50]. In a recent CFS study, elevated TGF-β were also reported [
15]. The method used by these investigators does not allow to assess the magnitude of the TGF-β concentrations, and there is little mention of potential confounder. For example, oral contraceptives induce platelet activation in humans [
51], and directly cause increased TGF-β concentrations in rats [
52].
These differences regarding sample handling might also be the explanation for the fact that previous studies found more cytokines to be differentially expressed in CFS/ME patients. A substantial proportion of studies included multiple cohorts in their analyses [
9,
31], and although this gives the opportunity to investigate a larger number of patients, including patients coming from geographically different regions results in an inherent danger of inaccurate conclusions. This is because sample handling may have been different, for example use of different centrifuges, differences in ambient temperature, variations in collection time, and storage. Such differences in pre-analytic sample handling and storage, were part of the explanation for the spurious reports on the role of murine retroviruses in CFS/ME [
53]. In addition, cytokine concentrations are known to be influenced by drug use. The use of non-steroidal anti-inflammatory drugs (NSAIDS), which are frequently used by CFS/ME patients, increase the production of various cytokines [
54,
55]. Differences in use of NSAIDS and other medication between patients and controls, might have explained the reported increased levels of pro-inflammatory cytokines in previous studies.
Interestingly, combining all inflammatory markers yields a prediction model containing 47 markers with a corrected AUC of 0.73. To control for optimism, a bootstrapping method was used, which yielded a high correction factor of 0.265. Some of the measured proteins have a positive association with CFS/ME (IL-6, CSF-1), whereas for others there was a negative association (BetaNGF, CXCL-6). This selection of inflammatory markers could be a starting point for further studies investigating potential diagnostic markers in CFS/ME.
According to the 95% confidence intervals, there was an inhibiting effect of anakinra on circulating CSF-1, IL-18R1 and ENRAGE and a stimulating effect on CXCL-9. Given the large numbers of cytokines tested, these findings have to be interpreted with caution. It is important to mention that IL-1β was not included in the analysis, and IL-α was already below the detection limit before treatment in 82% of samples. It was expected that there would be a significant decrease of IL-6 in the anakinra group, as IL-1 induces IL-6 production, and is frequently used as a readout for IL-1 activity [
56]. In previous studies, there was also a significant reduction of IL-6 concentrations after anakinra treatment. This was investigated in patients intravenously treated after stroke [
57] and patients treated with subcutaneous injections for heart failure [
58]. A possible explanation for the lack of a decrease in IL-6 concentrations is that in comparison to the situation in stroke patients where it has an important prognostic role [
59], CFS/ME patients exhibit no increase of this cytokine at baseline. In stroke and heart failure an inflammatory response in which IL-1 plays a key role is now well established, but it is possible that IL-1 does not play a role in CFS. Since drug adherence was excellent, which is also reflected by the significant increase of IL-1Ra in the anakinra treated group, it is unlikely that lack of compliance is an explanation for this result.
This study has several strengths. To our knowledge, PEA-based assays have not previously been performed in CFS/ME patients. Over the past few years, there has been a search for sensitive methods to measure multiple inflammatory markers simultaneously in order to find potential biomarkers for CFS/ME. However, this is most commonly performed using multiplex bead-based immunoassays, that have limited sensitivity and specificity [
20]. This is not the case for the PEA method, which has a much higher specificity as the signals can only be elicited by the cognate antibody pairs, while cross reactions between irrelevant antibody pairs are ignored [
21]. Another asset of this study is the inclusion of neighborhood controls. Each patient was asked to bring a healthy, sex- and age-matched control, and blood withdrawal of both patient and control took place at the same time. Pre-analytic processes were identical, which was not the case in most of the previously published biomarker studies in CFS/ME [
31,
41]. The third advantage of the current study is exclusion of patients who use medication, with the exception of oral contraceptives and paracetamol. CFS/ME patients frequently use a significant amount of medication, in a recent study 64% of patients used complementary and alternative medicine [
60]. Another study found that > 90% of CFS/ME patients use at least one drug or supplement, especially antidepressants, sedatives and muscle relaxants [
61].
A limitation of this study is the relatively small number of patients included measuring a large number of variables. However, this has been accounted for using the LASSO method for logistic regression, which is an elegant variable reduction method [
62]. However, considering the large factor for optimism, the prediction model has to be interpreted with caution. Another limitation of the current study is the fact that IL-1β was not measured in plasma samples, although the value of this measurement is limited as IL-1β is usually undetectable in peripheral blood, even with the PEA method.
Authors’ contributions
JWMM, HK, LAB and MER defined the research theme and designed the research methods. MER, JWMM, HK and EMB conducted the study and collected the data. MER, LJAC, HAM and EMB analysed the data. MER interpreted the results and wrote the first draft of the manuscript; the other authors reviewed and edited the manuscript. All authors read and approved the final manuscript.